Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

Brilacidin failed to meet the primary result in a first test against the new virus. It is not easy to be the new drug in the room.
https://www.reuters.com/article/us-fda-abbott/abbott-may-need-more-humira-studies-fda-staff-idUSBRE87N0IU20120824

*“Brilacidin is now among our best options to fight antimicrobial resistant strains of bacterial infections, one of the scariest global threats,” explained Vincenzo Carnevale, professor of research at CST’s Institute for Computational Molecular Science (ICMS). He noted that the last truly novel class of antimicrobial molecules—not an optimization of preexisting molecules—was approved by the U.S. Food and Drug Administration in 1987.*

I am happy to own some of this truly novel antimicrobial molecule.